1+ hour, 42+ min ago   (513+ words) Elena Sevillano Fernández describes SASAN-SPARING, a phase 2 multicenter Spanish trial enrolling 70 patients with T2–T4 N0M0 muscle-invasive bladder cancer eligible for cisplatin-based chemotherapy and cystectomy. Patients receive four cycles of gemcitabine plus cisplatin, then undergo restaging with TURBT, MRI, and molecular analysis including…...

1+ day, 3+ hour ago   (309+ words) UroToday Zachary Klaassen: Hi, my name is Zach Klaassen, urologic oncologist in Augusta, Georgia, and we are at ASCO 2026 in Chicago, Illinois And joined on UroToday by Dr Daniel Petrylak, who's a medical oncologist at Yale University Today we'll be…...

1+ day, 10+ hour ago   (744+ words) Oliver Sartor discusses AcTFirst, a randomized trial evaluating PSMA-617 actinium-225 in taxane-naive metastatic castration-resistant prostate cancer. Patients progressed on ADT and an ARPI, and the flexible control arm permits docetaxel or a second-line ARPI, with lutetium PSMA also allowed. Radiographic…...

1+ day, 10+ hour ago   (609+ words) Yijun Shen discusses phase two results from a single-arm study of SHR-A2102 plus adebrelimab as neoadjuvant therapy in muscle-invasive bladder cancer. SHR-A2102 is a nectin-4 antibody-drug conjugate with a topoisomerase I payload. Of 27 patients who underwent radical cystectomy, the pathologic…...

2+ day, 3+ hour ago   (1067+ words) UroToday...

2+ day, 9+ hour ago   (801+ words) Susan Halabi presents a ctDNA-based prognostic model for radiographic progression-free survival in mCRPC patients receiving first-line androgen receptor pathway inhibitors. The model was developed from plasma samples collected in the Alliance phase 3 trial of 1,311 patients using a Random Survival Forest…...

3+ day, 4+ hour ago   (687+ words) UroToday...

3+ day, 4+ hour ago   (1245+ words) Jason Hafron explains how independent urology practices can reliably adopt new intravesical bladder cancer therapies, using gemcitabine intravesical system (TAR-200) that carries a J-code, as the primary example for BCG-refractory disease. He describes clinical eligibility, payer financial clearance, drug acquisition…...

3+ day, 8+ hour ago   (665+ words) Michael Morris reviews phase two CONV01-alpha data, covering an actinium-labeled PSMA-targeting antibody that produces minimal salivary and no renal uptake, unlike lutetium-based peptide agents. The 35 patients had all received an ARPI, 80% had received chemotherapy, and the median prior lutetium PSMA…...

3+ day, 4+ hour ago   (766+ words) Renu Eapen surveys the current state and future directions of radioligand therapy in prostate cancer, using lutetium PSMA trial data across disease states to distinguish where standard-of-care use is established from settings still under active investigation. Dr. Eapen identifies low…...